Circulating Tumor Cells (CTCs) correlate with adverse prognosis in breast, colorectal, lung and prostate cancer patients. Little data is available for Renal Cell Carcinoma (RCC).
We designed a multicenter prospective observational study to assess the correlation between CTC counts and Progression Free Survival (PFS) in metastatic RCC patients treated with an anti-angiogenic tyrosine kinase inhibitor as a first-line regimen; Overall Survival (OS) and response were secondary objectives.